Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OKYO PharmaFRA:OK10 24 Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus rates FRA:OK10 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 963 Biotechnology companies, OKYO Pharma ranks better than 88.06% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for OKYO Pharma's Debt-to-Equity or its related term are showing as below:
FRA:OK10'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.08 Med: -0.23 Max: 0.02
Current: 0.02
During the past 13 years, the highest Debt-to-Equity Ratio of OKYO Pharma was 0.02. The lowest was -1.08. And the median was -0.23.
FRA:OK10's Debt-to-Equity is ranked better than 88.06% of 963
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:OK10: 0.02
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
OKYO Pharma Debt-to-Equity Related Terms
OKYO Pharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for OKYO Pharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OK10 vs ACET, ACRV, GOSS: Debt-to-Equity Comparison
For the Biotechnology subindustry, OKYO Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OKYO Pharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OKYO Pharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where OKYO Pharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OKYO Pharma (FRA:OK10) has a Debt-to-Equity of 0.00 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OKYO Pharma and its competitors. According to the industry distribution chart, OKYO Pharma ranks #115 out of 963 companies in the Biotechnology industry, placing it in the top 11.9%.
Is OKYO Pharma's Debt-to-Equity too high?
OKYO Pharma's current Debt-to-Equity is 0.00. Based on the distribution chart, OKYO Pharma ranks #115 out of 963 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, OKYO Pharma has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Debt-to-Equity compare to ACET and ACRV?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #115 out of 963 companies for Debt-to-Equity. This places OKYO Pharma in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on OKYO Pharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OKYO Pharma's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (FRA:OK10) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. OKYO Pharma's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For OKYO Pharma (FRA:OK10), the current Debt-to-Equity is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
24GF Score
Get the complete analysis for FRA:OK10
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OK10 has been successfully added to your 
